Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Rahul Khandelwal, Jayant D Vagha, Revat J Meshram, Ankita Patel
Digoxin, a cardiac glycoside derived from the foxglove plant ( Digitalis spp.), has been utilized for centuries in managing various cardiac conditions due to its ability to increase myocardial contractility and regulate heart rate. This comprehensive review explores the historical context, pharmacological properties, clinical applications, efficacy, safety profile, challenges, and future perspectives of digoxin. Tracing its journey from traditional medicine to modern cardiovascular therapeutics, we delve into its mechanism of action, therapeutic indications, and clinical guidelines...
March 2024: Curēus
#2
JOURNAL ARTICLE
Alla Adelkhanova, Prakash Raj Oli, Dhan Bahadur Shrestha, Jurgen Shtembari, Vivek Jha, Ghanshyam Shantha, George Michael Bodziock, Monodeep Biswas, Muhammad Omer Zaman, Nimesh K Patel
BACKGROUND AND AIM: Obesity affects nearly 650 million adults worldwide, and the prevalence is steadily rising. This condition has significant adverse effects on cardiovascular health, increasing the risk of hypertension, coronary artery disease, heart failure, and atrial fibrillation (AF). While anticoagulation for obese patients with AF is a well-established therapy for the prevention of thromboembolism, the safety and efficacy of different anticoagulants in this specific population are not well explored...
April 2024: Health Science Reports
#3
JOURNAL ARTICLE
Abel A Pavía-López, José A Magaña-Serrano, José A Cigarroa-López, Adolfo Chávez-Mendoza, José L Mayorga-Butrón, Diego Araiza-Garaygordobil, Juan B Ivey-Miranda, Gustavo F Méndez-Machado, Héctor González-Godínez, Luisa F Aguilera-Mora, Antonio Jordán-Ríos, Luis Olmos-Domínguez, Marcos J Olalde-Román, Emma M Miranda-Malpica, Zuilma Vázquez-Ortiz, Jorge Rayo-Chávez, Alexandra A Mendoza, Manlio F Márquez-Murillo, Sergio A Chávez-Leal, Amada Álvarez-San Gabriel, Marissa A Silva-García, Alex D Pacheco-Bouthiller, Jorge A Aldrete-Velazco, Carlos A Guizar-Sánchez, Efraín Gaxiola-López, Arturo Guerra-López, Lourdes Figueiras-Graillet, Gustavo Sánchez-Miranda, Genaro H Mendoza-Zavala, Moisés Aceves-García, Adolfo Chávez-Negrete, Marisol Arroyo-Hernández, Bertha B Montaño-Velázquez, Luis F Romero-Moreno, María M Baquero-Hoyos, Liliana Velasco-Hidalgo, Ana L Rodríguez-Lozano, Nancy E Aguilar-Gómez, Mario Rodríguez-Vega, Jorge E Cossío-Aranda
Chronic heart failure continues to be one of the main causes of impairment in the functioning and quality of life of people who suffer from it, as well as one of the main causes of mortality in our country and around the world. Mexico has a high prevalence of risk factors for developing heart failure, such as high blood pressure, diabetes, and obesity, which makes it essential to have an evidence-based document that provides recommendations to health professionals involved in the diagnosis and treatment of these patients...
2024: Archivos de Cardiología de México
#4
JOURNAL ARTICLE
Alexis R Bogannam, Ewan McNicol, Kevin DeLeonardo, Ashwini Ranade, Kathy Zaiken
Background: Recent clinical trials and guideline updates have highlighted the efficacy and safety of sodium-glucose cotransporter-2 inhibitor (SGLT2i) use in patients with type 2 diabetes (T2D) and comorbidities including atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or heart failure (HF). Objective: This study assesses the rates of guideline-based prescribing of SGLT2i in patients with T2D and one or more of the following comorbidities: ASCVD, CKD, or HF, prior to and after the 2022 American Diabetes Association (ADA) guideline publication within the Atrius Health clinical pharmacy, internal medicine, and specialty medicine departments...
April 22, 2024: Journal of Pharmacy Practice
#5
JOURNAL ARTICLE
Suguru Okami, Coralie Lecomte, Hanaya Raad, Mireia Aguila, Zuzana Mohrova, Makiko Takeichi, Takanori Tsuchiya, Christoph Ohlmeier, Thomas Evers, Alexander Michel
Currently, the utilization patterns of medications for heart failure (HF) after worsening HF events remain unelucidated in Japan. Here, we conducted a retrospective cohort study evaluating the changes in HF drug utilization patterns in 6 months before and after hospitalizations for HF. The adherence to newly initiated HF medications was evaluated based on the proportion of days covered (PDC) and persistence as continuous treatment episodes among new users. The study included 9091 patients hospitalized for HF between January 2016 and September 2019, including 2735 (30...
April 20, 2024: Scientific Reports
#6
JOURNAL ARTICLE
Khoirur Rijal Ashsholih, Taiichi Takasaki, Mayu Tomota, Taika Tokumoto, Seimei Go, Shogo Emura, Masamichi Ozawa, Shinya Takahashi
BACKGROUND: Post-myocardial infarction (MI) ventricular septal perforation (VSP) is a rare but life-threatening complication. Surgical repair is challenging and carries significant risks, particularly in the context of recurrent VSPs. This case study presents a patient with recurrent VSP after initial surgical repair following myocardial infarction. CASE PRESENTATION: A 65-year-old male were re-administered to our hospital due to recurrent VSP. He was during follow up after undergone emergency VSP closure surgery 2 months earlier, utilizing the bovine double patch technique via left ventriculostomy...
April 20, 2024: Journal of Cardiothoracic Surgery
#7
REVIEW
Kiyoyuki Eishi, Junichiro Eishi, Ichiro Matsumaru, Mizuki Sumi, Kikuko Obase, Takashi Miura
The indication for surgery for tricuspid regurgitation (TR) has reached a major turning point. It has become clear that the presence of moderate or severe TR alone worsens the prognosis of life, and the previous guidelines of Japanese Circulation Society, in which the indication for surgery was recommended at the timing of "right heart failure difficult to treat medically," now recommends surgery with a trigger of "repeated right heart failure" in the 2020 edition. In addition, a new repair technique targeting at subvalvular structure has been developed for end-stage TR to overcome a high TR recurrence rate that is associated with severe right ventricular enlargement and leaflet tethering...
April 20, 2024: General Thoracic and Cardiovascular Surgery
#8
JOURNAL ARTICLE
Andrew Krumerman, Luigi Di Biase, Edward Gerstenfeld, Timm Dickfeld, Nishant Verma, Leonardo Liberman, Richard Amara, Ardit Kacorri, Lori Crosson, Alan Wilk, Kevin J Ferrick
BACKGROUND: Premature ventricular contractions (PVCs) burden is a risk factor for heart failure and cardiovascular death in patients with structural heart disease. Long-term ECG monitoring can have a significant impact on PVC burden evaluation by further defining PVC distribution patterns. OBJECTIVE: This study aimed to ascertain the optimal duration of ECG monitoring to characterize PVC burden and understand clinical characteristics associated with frequent PVCs and NSVT in a large US cohort...
April 17, 2024: Heart Rhythm: the Official Journal of the Heart Rhythm Society
#9
JOURNAL ARTICLE
De-Yu Miao, Zu-Long Wang, Chen-Ming Zhang, Jin-Hu Jia, Ming-Xian Meng
OBJECTIVE: In order to exploring Erectile Dysfunction(ED) syndrome and syndrome differentiation based on latent structure to provide objective evidence to support Traditional Chinese Medicine(TCM) dialectic. METHODS: Cases and clinical experience in the treatment of erectile dysfunction in Chinese medicine in CNKI, Wanfang Database, cqVIP Database, were searched. Time from the database construction to January, 2023. Extraction and specification of symptom data with reference to national standards...
December 2023: Zhonghua Nan Ke Xue, National Journal of Andrology
#10
JOURNAL ARTICLE
Giovanni Davogustto, Quinn S Wells, Frank E Harrell, Stephen J Greene, Dan M Roden, Lynne W Stevenson
BACKGROUND: An angiotensin receptor-neprilysin inhibitor (ARNI) is the preferred renin-angiotensin system (RAS) inhibitor for heart failure with reduced ejection fraction (HFrEF). Among eligible patients, insurance status and prescriber concern regarding out-of-pocket costs may constrain early initiation of ARNI and other new therapies. OBJECTIVES: In this study, the authors sought to evaluate the association of insurance and other social determinants of health with ARNI initiation at discharge from HFrEF hospitalization...
April 4, 2024: JACC. Heart Failure
#11
REVIEW
Tyler Drake, Adrienne Landsteiner, Lisa Langsetmo, Roderick MacDonald, Maylen Anthony, Caleb Kalinowski, Kristen Ullman, Charles J Billington, Anjum Kaka, Shahnaz Sultan, Timothy J Wilt
BACKGROUND: Newer diabetes medications may have beneficial effects on mortality, cardiovascular outcomes, and renal outcomes. PURPOSE: To evaluate the effectiveness, comparative effectiveness, and harms of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP1) agonists, dipeptidyl peptidase-4 (DPP4) inhibitors, and long-acting insulins as monotherapy or combination therapy in adults with type 2 diabetes mellitus (T2DM). DATA SOURCES: MEDLINE and EMBASE for randomized controlled trials (RCTs) published from 2010 through January 2023...
April 19, 2024: Annals of Internal Medicine
#12
JOURNAL ARTICLE
Amir Qaseem, Adam J Obley, Tatyana Shamliyan, Lauri A Hicks, Curtis S Harrod, Carolyn J Crandall
DESCRIPTION: The American College of Physicians (ACP) developed this clinical guideline to update recommendations on newer pharmacologic treatments of type 2 diabetes. This clinical guideline is based on the best available evidence for effectiveness, comparative benefits and harms, consideration of patients' values and preferences, and costs. METHODS: This clinical guideline is based on a systematic review of the effectiveness and harms of newer pharmacologic treatments of type 2 diabetes, including glucagon-like peptide-1 (GLP-1) agonists, a GLP-1 agonist and glucose-dependent insulinotropic polypeptide agonist, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and long-acting insulins, used either as monotherapy or in combination with other medications...
April 19, 2024: Annals of Internal Medicine
#13
JOURNAL ARTICLE
Stephen J Greene, Hanna K Gaggin, Mo Zhou, Lori D Bash, Dominik Lautsch, Laurence Djatche, Yan Song, James Signorovitch, Andra S Stevenson, Robert O Blaustein, Javed Butler
AIMS: Patients with HFrEF and worsening HF events (WHFE) are at particularly high risk and urgently need disease-modifying therapy. CHART-HF assessed treatment patterns and reasons for medication decisions among HFrEF patients with and without WHFE. METHODS AND RESULTS: CHART-HF collected retrospective electronic medical records of outpatients with HF and EF < 45% between 2017-2019 from a nationwide panel of 238 cardiologists (458 patients) and the Geisinger Health System (GHS) medical record (1000 patients)...
April 19, 2024: ESC Heart Failure
#14
JOURNAL ARTICLE
Kanako Teramoto, Wan Ting Tay, Jasper Tromp, Wouter Ouwerkerk, Tiew-Hwa Katherine Teng, Chanchal Chandramouli, Oi Wah Liew, Jenny Chong, Katrina K Poppe, Mayanna Lund, Gerry Devlin, Richard W Troughton, Robert N Doughty, Arthur Mark Richards, Carolyn S P Lam
BACKGROUND: The relationship of serial NT-proBNP (N-terminal pro-B-type natriuretic peptide) measurements with changes in cardiac features and outcomes in heart failure (HF) remains incompletely understood. We determined whether common clinical covariates impact these relationships. METHODS AND RESULTS: In 2 nationwide observational populations with HF, the relationship of serial NT-proBNP measurements with serial echocardiographic parameters and outcomes was analyzed, further stratified by HF with reduced versus preserved left ventricular ejection fraction, inpatient versus outpatient enrollment, age, obesity, chronic kidney disease, atrial fibrillation, and attainment of ≥50% guideline-recommended doses of renin-angiotensin system inhibitors and β-blockers...
April 19, 2024: Journal of the American Heart Association
#15
JOURNAL ARTICLE
Michele Massimo Gulizia, Fabio Maria Turazza, Pietro Ameri, Marco Alings, Ronan Collins, Leonardo De Luca, Marcello Di Nisio, Donata Lucci, Domenico Gabrielli, Stefan Janssens, Iris Parrini, Fausto J Pinto, Jose Luis Zamorano, Furio Colivicchi
BACKGROUND: Cancer is an important condition associated with the development of atrial fibrillation (AF). The objectives of the BLITZ-AF Cancer study were to collect real-life information on the clinical profile and use of antithrombotic drugs in patients with AF and cancer to improve clinical management, as well as the evaluation of the association between different antithrombotic treatments (or their absence) and the main clinical events. METHODS: European multinational, multicenter, prospective, non-interventional study conducted in patients with AF (electrocardiographically confirmed) and cancer occurring within 3 years...
May 2024: Giornale Italiano di Cardiologia
#16
REVIEW
Zina Jawadi, Rosemary He, Pratyaksh K Srivastava, Gregg C Fonarow, Suzan O Khalil, Srikanth Krishnan, Eleazar Eskin, Jeffrey N Chiang, Ali Nsair
Existing risk prediction models for hospitalized heart failure patients are limited. We identified patients hospitalized with a diagnosis of heart failure between 7 May 2013 and 26 April 2022 from a large academic, quaternary care medical centre (training cohort). Demographics, medical comorbidities, vitals, and labs were collected and were used to construct random forest machine learning models to predict in-hospital mortality. Models were compared with logistic regression, and to commonly used heart failure risk scores...
April 18, 2024: ESC Heart Failure
#17
REVIEW
Brianna Wagaman
BACKGROUND: Cardiogenic shock (CS), a complex and life-threatening medical condition, has an astounding hospital mortality rate spanning from 40 % to 59 %. Frequently, CS requires the use of pulmonary artery catheters (PACs) for management. OBJECTIVE: This literature review aims to investigate the relationship between PAC utilization in CS patients and in-hospital 30-day mortality rates compared to noninvasive vital sign monitoring alone. METHODS: An integrative literature search was conducted from January 1, 2003, until August 1, 2023...
April 17, 2024: Heart & Lung: the Journal of Critical Care
#18
JOURNAL ARTICLE
Xuelin Zhang, Grace W K Ho, Yim Wah Mak
BACKGROUND: Chronic heart failure (CHF) poses a significant burden on both patients and their family caregivers (FCs), as it is associated with psychological distress and impaired quality of life (QOL). Acceptance and Commitment Therapy (ACT) supports QOL by focusing on value living and facilitates acceptance of psychological difficulties by cultivating psychological flexibility. A protocol is presented that evaluates the effectiveness of a dyad ACT-based intervention delivered via smartphone on QOL and other related health outcomes compared with CHF education only...
2024: PloS One
#19
REVIEW
Sivaram Neppala, Jemema Rajan, Eric Yang, Ralph A DeFronzo
PURPOSE OF REVIEW: What is new? Cardiovascular disease (CVD) is the leading cause of mortality in type 2 diabetes (T2D) individuals. Of the major risk factors for CVD, less than 10% of T2D people meet the American Diabetes Association/American Heart Association recommended goals of therapy. The present review examines how much of the absolute cardiovascular (CV) risk in type 2 diabetes patients can be explained by major CV intervention trials. RECENT FINDINGS: Multiple long-term cardiovascular (CV) intervention trials have examined the effect of specific target-directed therapies on the MACE endpoint...
April 18, 2024: Current Cardiology Reports
#20
JOURNAL ARTICLE
Maryam Khorramshahi Bayat, Wandy Chan, Karen Hay, Scott McKenzie, Polash Adhikari, Gavin Fincher, Faye Jordan, Isuru Ranasinghe
BACKGROUND: Spot urinary sodium concentration (UNa) is advocated in guidelines to assess diuretic response and titrate dosage in acute heart failure (AHF). However, no randomised controlled trial data exists to support this approach. We performed a prospective pilot trial to investigate the feasibility of this approach. METHODS: 60 patients with AHF (n = 30 in each arm) were randomly assigned to titration of loop diuretics for the first 48 hours of admission according to UNa levels (intervention arm) or based on clinical signs and symptoms of congestion (standard care arm)...
April 17, 2024: European Heart Journal. Quality of Care & Clinical Outcomes
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
